ReviewAnnals of general psychiatry2024
Association between rTMS-induced changes in inflammatory markers and improvement in psychiatric diseases: a systematic review.
Review in Annals of general psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cognitive rehabilitation in schizophrenia research: a bibliometric and visualization analysis.Frontiers in psychiatry · 2024Pooled it
- Non-invasive brain stimulation as an experimental treatment approach for bulimia nervosa and binge eating disorders: A meta-analysis and systematic review of literature.Indian journal of psychiatry · 2026Review
- Physical factor therapies for insomnia: a narrative review of mechanisms, clinical evidence, and phenotype-guided applications.Frontiers in psychiatry · 2026Review
- Potential Epigenetic Mechanisms of High-Frequency rTMS in the Treatment of Major Depression: A Brief Report of Current Evidence.Noro psikiyatri arsivi · 2026Article
- Exploring potential value of neutrophil extracellular traps in major depressive disorder.Frontiers in immunology · 2026Article
- Sequential bilateral rTMS combined with fluoxetine for anhedonic depression in adolescents: clinical efficacy and peripheral inflammatory profiles.Frontiers in psychiatry · 2026Article
- Putative Neuroimmune Mechanisms and Candidate Biomarkers of rTMS Efficacy in Improving Negative Symptoms of Schizophrenia: Evidence Boundaries and Translational Pathways.Neuropsychiatric disease and treatment · 2026Review
- Review
- Inflammatory and Oxidative Biological Profiles in Mental Disorders: Perspectives on Diagnostics and Personalized Therapy.International journal of molecular sciences · 2025Review
- The neurobiological foundation of effective repetitive transcranial magnetic brain stimulation in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Association between white blood cell counts and the efficacy on cognitive function after rTMS intervention in schizophrenia.Schizophrenia (Heidelberg, Germany) · 2025Article
- Immune-inflammatory, neuroplastic, and epigenetic effects of electroconvulsive therapy in mood disorders: an overview of recent studies.Frontiers in psychiatry · 2025Review
- Effect of intermittent theta burst stimulation of the left DLPFC on cognitive function and inflammatory markers in post-stroke cognitive impairment: a randomized controlled trial.Frontiers in psychiatry · 2025Article
- Combination Therapy Against Mood and Anxiety Disorders: Association Between Efficacy and White Blood Cell Count.Neuropsychiatric disease and treatment · 2025Article
- Revolutionizing Neuroimmunology: Unraveling Immune Dynamics and Therapeutic Innovations in CNS Disorders.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRepetitive transcranial magnetic stimulation (rTMS) has recently gained relevance in treating different psychiatric disorders. Limited evidence suggests that the beneficial effects of rTMS on psychopathology could be at least partly mediated through changes in inflammatory response. This systematic review summarizes the literature on whether rTMS can modulate inflammatory markers and thus positively influence the course of psychiatric illnesses. MATERIALS AND
methodsA systematic review of rTMS and inflammatory markers in psychiatric diseases was conducted according to PRISMA guidelines. Information on the association between rTMS treatment response and changes of inflammatory markers was extracted. The quality of the studies was assessed using the National Heart, Lung, and Blood Institute for human studies and the Systematic Review Center for Laboratory Animal Experimentation for animal studies.
resultsThis review includes 17 studies (2 animal and 15 human studies) on the relationship between rTMS treatment response and changes of inflammatory markers. Positive changes in microglial activity and anti-inflammatory effects were associated with behavioral improvement in animal models of depression. However, these findings have not been consistently replicated in human studies focusing on treatment-resistant depression. While several studies reported rTMS-induced alterations in peripheral inflammatory markers, only two could demonstrate their association to clinical treatment response. Notably, most studies showed poor or moderate quality in the bias assessment.
conclusionsWhile certain human studies suggest an association between rTMS-induced anti-inflammatory effects and improvement in psychopathology, heterogeneity, and underpowered analyses constrain the generalizability of these results. The discrepancy between animal and human findings highlights the need for larger, standardized human studies.
trial registration(PROSPERO Registration: CRD42023492732).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.